Neoptix

Each vial contains: Parecoxib Sodium equivalent to Parecoxib 40 mg.

Short-term treatment of post-operative pain.

The recommended dose is 40 mg administered intravenously (I.V.) or intramuscularly (I.M.), followed every 6 to 12 hours by 20 mg or 40 mg as required, not to exceed 80 mg per day.

Hypersensitivity to the active substance.
Patients with a history of hypersensitivity to sulphonamides.
Patients who have experienced bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or allergic-type. Reactions after taking acetylsalicylic acid or NSAIDs or other cyclooxygenase-2 (COX-2) selective inhibitors. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients.
Third trimester of pregnancy and lactation.
Severe hepatic impairment (Child-Pugh >9).
Active peptic ulceration or gastrointestinal bleeding.
Inflammatory bowel disease.
Severe congestive heart failure.
Treatment of post-operative pain immediately following coronary artery bypass graft (CABG) surgery and should not be used in this setting.

Parecoxib cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to disease exacerbation. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids.

Gastrointestinal disorders ie, nausea.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

M01AH04 - parecoxib ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, coxibs.

K